Nanoparticles (NPs)-mediated systemic mRNA delivery to reverse trastuzumab resistance for effective breast cancer therapy
Acta Pharmaceutica Sinica B · 2023-03 · 13 (3) · 955-966
DOI: 10.1016/j.apsb.2022.09.021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Pharmaceutica Sinica B, 2023-03. Verfasst von Zhihui Dong und 6 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Y…. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Guangdong Science and Technology Department, Guangzhou Municipal Science and Technology Bureau, Natural Science Foundation of Guangdong Province.
Abstract (Originalsprache)
Monoclonal antibody-based therapy has achieved great success and is now one of the most crucial therapeutic modalities for cancer therapy. The first monoclonal antibody authorized for treating human epidermal growth receptor 2 (HER2)-positive breast cancer is trastuzumab. However, resistance to trastuzumab therapy is frequently encountered and thus significantly restricts the therapeutic outcomes. To address this issue, tumor microenvironment (TME) pH-responsive nanoparticles (NPs) were herein developed for systemic mRNA delivery to reverse the trastuzumab resistance of breast cancer (BCa). This nanoplatform is comprised of a methoxyl-poly (ethylene glycol)-b-poly (lactic-co-glycolic acid) copolymer with a TME pH-liable linker (Meo-PEG-Dlink m -PLGA) and an amphiphilic cationic lipid that can complex PTEN mRNA via electrostatic interaction. When the long-circulating mRNA-loaded NPs build up in the tumor after being delivered intravenously, they could be efficiently internalized by tumor cells due to the TME pH-triggered PEG detachment from the NP surface. With the intracellular mRNA release to up-regulate PTEN expression, the constantly activated PI3K/Akt signaling pathway could be blocked in the trastuzumab-resistant BCa cells, thereby resulting in the reversal of trastuzumab resistance and effectively suppress the development of BCa.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.
- RNA Biomedical Institute, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.
- School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou 511442, China.
Förderung
- Guangdong Science and Technology Department
- Guangzhou Municipal Science and Technology Bureau
- Natural Science Foundation of Guangdong Province
- National Natural Science Foundation of China
Zitieren
APA
Dong, Z., Huang, Z., Li, S., Wang, Y., Yao, Y., Yang, X., & Xu, X. (2023). Nanoparticles (NPs)-mediated systemic mRNA delivery to reverse trastuzumab resistance for effective breast cancer therapy. Acta Pharmaceutica Sinica B, 13(3), 955-966. https://doi.org/10.1016/j.apsb.2022.09.021
Vancouver
Dong Z, Huang Z, Li S, Wang Y, Yao Y, Yang X, et al. Nanoparticles (NPs)-mediated systemic mRNA delivery to reverse trastuzumab resistance for effective breast cancer therapy. Acta Pharmaceutica Sinica B. 2023;13(3):955-966. doi:10.1016/j.apsb.2022.09.021
BibTeX
@article{Dong2023,
author = {Dong, Zhihui and Huang, Zhuoshan and Li, Senlin and Wang, Ying and Yao, Yandan and Yang, Xianzhu and Xu, Xiaoding},
title = {Nanoparticles (NPs)-mediated systemic mRNA delivery to reverse trastuzumab resistance for effective breast cancer therapy},
journal = {Acta Pharmaceutica Sinica B},
year = {2023},
volume = {13},
number = {3},
pages = {955--966},
doi = {10.1016/j.apsb.2022.09.021}
}
EUVIMED